Vaxart (NASDAQ:VXRT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The […]
Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first.
Four clinical trials for COVID-19 and norovirus oral tablet vaccine candidates are currently ongoing Company now operates two GMP manufacturing plants to.